Want to see PRLD full AI Analyst Report?
PRLD Stock Chart & Stats
$3.89
$0.75(19.28%)
At close: 4:00 PM EDT
$3.89
$0.75(19.28%)
Day’s Range― - ―
52-Week Range$0.75 - $5.69
Previous Close$4.6
Volume1.86M
Average Volume (3M)256.05K
Market Cap
$402.21M
Enterprise Value$218.39
Total Cash (Recent Filing)$81.55M
Total Debt (Recent Filing)$17.72M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 19, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding64,917,175
10 Day Avg. Volume194,393
30 Day Avg. Volume256,051
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.25
Price to Sales (P/S)18.38
P/FCF Ratio-3.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside118.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$37.93M
Bulls Say, Bears Say
Bulls Say
Improving Revenue TrendConsistent multi-year revenue growth signals early commercial traction from collaborations and licensing, demonstrating the company can generate partner-funded revenue. This trend supports sustainability of R&D investment and reduces sole reliance on equity raises if maintained over subsequent quarters.
Extended Cash Runway And Manageable DebtA sizeable financing plus existing cash gives > ~18 months runway and, combined with modest debt (~$17.7M, ~0.29 D/E), materially lowers near-term liquidity risk. This durable extension enables multi-quarter clinical development without immediate financing pressure.
Advancing Pipeline & Leadership StrengthEntry into Phase 1 and multiple preclinical programs diversify the value drivers and reduce binary single-program risk. Presenting preclinical data and adding an experienced CMO improve development execution and partnerability, supporting long-term program de-risking and licensing potential.
Bears Say
Sustained Negative Cash FlowMeaningful and persistent cash burn indicates the company is not self-funding R&D and will remain dependent on external capital until commercialization. Continued negative cash flow strains flexibility and raises dilution or partnership reliance risk if clinical progress slows.
Material Decline In Shareholders' EquityA steep erosion of equity reduces the balance-sheet cushion for absorbing setbacks and increases financial vulnerability. Lower equity can raise borrowing costs, limit funding options, and amplify dilution pressure on shareholders during subsequent financings.
No Commercial Products; Funding RelianceAs a clinical-stage biotech without marketed products, revenue is irregular and milestone-driven. This structural business model creates ongoing reliance on partner deals and capital markets, leaving program continuity vulnerable to trial setbacks and shifting partner priorities.
Prelude Therapeutics News
PRLD FAQ
What was Prelude Therapeutics’s price range in the past 12 months?
Prelude Therapeutics lowest stock price was $0.75 and its highest was $5.69 in the past 12 months.
What is Prelude Therapeutics’s market cap?
Prelude Therapeutics’s market cap is $402.21M.
When is Prelude Therapeutics’s upcoming earnings report date?
Prelude Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 18 days.
How were Prelude Therapeutics’s earnings last quarter?
Prelude Therapeutics released its earnings results on May 12, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.252 by $0.122.
Is Prelude Therapeutics overvalued?
According to Wall Street analysts Prelude Therapeutics’s price is currently Undervalued.
Does Prelude Therapeutics pay dividends?
Prelude Therapeutics does not currently pay dividends.
What is Prelude Therapeutics’s EPS estimate?
Prelude Therapeutics’s EPS estimate is -0.2.
How many shares outstanding does Prelude Therapeutics have?
Prelude Therapeutics has 64,917,175 shares outstanding.
What happened to Prelude Therapeutics’s price movement after its last earnings report?
Prelude Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.252. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Prelude Therapeutics?
Currently, no hedge funds are holding shares in PRLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prelude Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (118.51% Upside)
$8.50 (118.51% Upside)
Blogger Sentiment
Bullish
PRLD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 11.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.30%
Trailing 12-Months
Company Description
Prelude Therapeutics
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
PRLD Stock 12 Month Forecast
Average Price Target
$8.50
▲(118.51% Upside)
Technical Analysis
Ownership Overview
36.92% Insiders
2.39% Mutual Funds
37.60% Other Institutional Investors
17.96% Public Companies and
Individual Investors